Histoplasma capsulatum prosthetic valve endocarditis treated with oral isavuconazole
Abstract
Histoplasma capsulatum remains the most common cause of systemic fungal infections in the United States, with severe cases occurring in older adults, immunosuppressed individuals, and those with lung disease. Despite its prevalence in systemic and pulmonary illness, histoplasmosis endocarditis is an unlikely source of mycotic endocarditis, with limited updated guidelines on antifungal therapy. We present a case of artificial valve histoplasma endocarditis requiring surgery and antifungal therapy. Isavuconazole was selected through shared decision-making due to concerns about the tolerability of traditional agents. The patient was successfully treated with a combination of aortic valve replacement and isavuconazole therapy.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Understanding the factors influencing fall armyworm (Spodoptera frugiperda J.E. Smith) damage in African smallholder maize fields and quantifying its impact on yield. A case study in Eastern Zimbabwe
- Alarming situation of emerging H5 and H7 avian influenza and effective control strategies
- Livestock and food security: vulnerability to population growth and climate change
- Atmosphere–ocean oxygen and productivity dynamics during early animal radiations
- Characterization of the global distribution and diversified plasmid reservoirs of the colistin resistance gene mcr-9
- The global seroprevalence of Toxoplasma gondii in pigs: A systematic review and meta-analysis
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.